Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gastroenterology

• Publication date

  2012-11-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1053/j.gastro.2012.07.099PMID 22841787PMCID PMC3482543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplementary Figure 2

  2014cited by this paper
• Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.

  2012cited by this paper
• Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

  2012cited by this paper
• Toll-like receptors.

  2011cited by this paper
• Enteric dysbiosis associated with a mouse model of alcoholic liver disease

  2011cited by this paper
• Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology

  2011cited by this paper
• Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis

  2011cited by this paper
• Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5

  2010cited by this paper
• Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis

  2009cited by this paper
• Intestinal mucosal barrier function in health and disease

  2009cited by this paper
• Nod2 regulates the host response towards microflora by modulating T cell function and epithelial permeability in mouse Peyer's patches

  2009cited by this paper
• Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits

  2008cited by this paper
• The critical role of toll‐like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88

  2008cited by this paper
• Role of TLR9 in hepatic stellate cells and experimental liver fibrosis.

  2008cited by this paper
• Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites.

  2007cited by this paper
• TLR4 enhances TGF-beta signaling and hepatic fibrosis.

  2007cited by this paper
• MyD88-mediated signals induce the bactericidal lectin RegIIIγ and protect mice against intestinal Listeria monocytogenes infection

  2007cited by this paper
• TLR4 enhances TGF-β signaling and hepatic fibrosis

  2007cited by this paper
• Roles of Rho/ROCK and MLCK in TNF‐α‐induced changes in endothelial morphology and permeability

  2007cited by this paper
• Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure

  2006cited by this paper
• LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice.

  2006cited by this paper
• FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses.

  2006cited by this paper
• Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease

  2006cited by this paper
• Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice.

  2005cited by this paper
• Mesenteric Th1 polarization and monocyte TNF‐α production: First steps to systemic inflammation in rats with cirrhosis

  2005cited by this paper
• Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo.

  2005cited by this paper
• Deaths: final data for 2002.

  2004cited by this paper
• A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease.

  2002cited by this paper
• Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting.

  2002cited by this paper
• Bacterial translocation of enteric organisms in patients with cirrhosis.

  2001cited by this paper
• The Role of Tumor Necrosis Factor-α in Liver Toxicity, Inflammation, and Fibrosis Induced by Carbon Tetrachloride

  2001cited by this paper
• The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride.

  2001cited by this paper
• Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin.

  1998cited by this paper
• Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha.

  1998cited by this paper
• Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter

  1995cited by this paper
• Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation.

  1995cited by this paper
• Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth.

  1990cited by this paper

• Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation.

  2025cites this paper
• Investigating Intestinal Farnesoid X Receptor functions at the Intestinal Mucosal Barrier and in the Intestinal Microbiota in a Biliary Obstruction Mouse Model.

  2025cites this paper
• Alcohol, Aging, and the Gut Microbiome: Intersections of Immunity, Barrier Dysfunction, and Disease.

  2025cites this paper
• Mesenchymal stem cell and exosome-based therapy for liver diseases: can it overcome conventional therapeutic inconsistencies?

  2025cites this paper
• Unlocking the potential: very-low-energy ketogenic therapy in obesity-related disorders

  2025cites this paper
• Lycopene improves cisplatin induced hepatointestinal injury in rats by modulating the microbe-gut-liver axis.

  2025cites this paper
• Protective effects of jiawei yupingfeng polysaccharides on cyclophosphamide-induced intestinal injury in mice.

  2025cites this paper
• Activation of intestinal endogenous retroviruses by alcohol exacerbates liver disease

  2025cites this paper
• The gut-liver axis in hepatobiliary diseases

  2024cites this paper
• Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications

  2024cites this paper
• Gut microbiota in MAFLD: therapeutic and diagnostic implications

  2024cites this paper
• Viral Liver Disease and Intestinal Gut–Liver Axis

  2024cites this paper
• Probiotics, prebiotics and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.

  2023cites this paper
• Clonorchis sinensis aggravates biliary fibrosis through promoting IL-6 production via toll-like receptor 2-mediated AKT and p38 signal pathways

  2023cites this paper
• Metabolomic Profiling of Obese Patients with Altered Intestinal Permeability Undergoing a Very Low-Calorie Ketogenic Diet

  2023cites this paper
• Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis.

  2023cites this paper
• Effect of ursodeoxycholic acid on the intestinal microbiota in children with chronic liver disease

  2023cites this paper
• Inflammatory Milieu Related to Dysbiotic Gut Microbiota Promotes Tumorigenesis of Hepatocellular Carcinoma

  2023cites this paper
• Microbial sensing in the intestine

  2023cites this paper
• Intestinal permeability and its role in the pathogenesis and progress of non-alcoholic fatty liver disease. Review

  2023cites this paper
• The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective

  2022cites this paper
• Preventive Mechanism of Lycopene on Intestinal Toxicity Caused by Cyclophosphamide Chemotherapy in Mice by Regulating TLR4-MyD88/TRIF-TRAF6 Signaling Pathway and Gut-Liver Axis

  2022cites this paper
• Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.

  2022cites this paper
• Intestinal microecology in mice bearing diethylnitrosamine-induced primary hepatocellular carcinoma.

  2022cites this paper
• Liver cirrhosis and immune dysfunction.

  2022cites this paper
• Dysbiosis and intestinal inflammation caused by Salmonella Typhimurium in mice can be alleviated by preadministration of a lytic phage.

  2022cites this paper
• Upregulation of cadherin‐11 contributes to cholestatic liver fibrosis

  2022cites this paper
• Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice

  2021cites this paper
• Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.

  2021cites this paper
• Systemic Immunoregulatory Consequences of Gut Commensal Translocation.

  2021cites this paper
• Intestinal Barrier and Permeability in Health, Obesity and NAFLD

  2021cites this paper
• Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis.

  2021cites this paper
• Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients

  2021cites this paper
• Herb-Partitioned Moxibustion Improves Crohn's Disease-Associated Intestinal Fibrosis by Suppressing the RhoA/ROCK1/MLC Pathway

  2021cites this paper
• Host–Microbiota Interactions in Liver Inflammation and Cancer

  2021cites this paper
• Epithelial Barrier Function

  2020cites this paper
• Non-Alcoholic Fatty Liver Disease: A 360-degree Overview

  2020cites this paper
• Pattern Recognition Receptors: Significance of Expression in the Liver

  2020cites this paper
• The role of the gut microbiome in graft fibrosis after pediatric liver transplantation

  2020cites this paper
• Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk

  2020cites this paper
• The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease.

  2020cites this paper
• Toll‐like Receptors in Liver Disease

  2020cites this paper
• A Story of Liver and Gut Microbes: How Does the Intestinal Flora Affect Liver Disease? A Review of the Literature.

  2020cites this paper
• Mechanisms of Fibrogenesis in NASH

  2020cites this paper
• IMMUNE MECHANISMS FOR THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS

  2020cites this paper
• Contributions of HO-1-Dependent MAPK to Regulating Intestinal Barrier Disruption

  2020cites this paper
• Role of the intestinal microbiome in liver fibrosis development and new treatment strategies.

  2019cites this paper
• Gut Abnormalities: New Insights Into the Pathogenesis of Acetaminophen‐Induced Liver Injury?

  2019cites this paper
• Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice

  2019cites this paper
• Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis

  2019influential citation
• Emerging roles of bile acids in mucosal immunity and inflammation

  2019cites this paper
• Protective Effect of Ursolic Acid on the Intestinal Mucosal Barrier in a Rat Model of Liver Fibrosis

  2019cites this paper
• Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation

  2019cites this paper
• The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease

  2018cites this paper
• MicroRNA-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation of obstructive jaundice-induced fibrosis in mice.

  2018cites this paper
• The gut–liver axis and the intersection with the microbiome

  2018cites this paper
• Publisher Correction: The gut–liver axis and the intersection with the microbiome

  2018cites this paper
• Enteric dysbiosis, gut barrier and liver disease.

  2018cites this paper
• Proteomic-genomic adjustments and their confluence for elucidation of pathways and networks during liver fibrosis.

  2018cites this paper
• Lactobacillus Aggravate Bile Duct Ligation-Induced Liver Inflammation and Fibrosis in Mice

  2018cites this paper
• Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL‐37

  2018cites this paper
• Gut Microbiota’s Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics

  2018cites this paper
• Gut microbiota translocation promotes autoimmune cholangitis.

  2018cites this paper
• Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice

  2018cites this paper
• Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short‐Chain Fatty Acids in Experimental Cirrhosis

  2018cites this paper
• Type 1 Diabetes: an Association Between Autoimmunity, the Dynamics of Gut Amyloid-producing E. coli and Their Phages

  2018cites this paper
• Toll-like receptors in the pathogenesis of pulmonary fibrosis.

  2017cites this paper
• Developmental origins of NAFLD: a womb with a clue

  2017cites this paper
• Role of intestinal microbiota and metabolites on gut homeostasis and human diseases

  2017cites this paper
• Macrophage Phenotype in Liver Injury and Repair

  2017cites this paper
• Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus

  2017cites this paper
• Hepatic stellate cells as key target in liver fibrosis.

  2017cites this paper
• Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats

  2017cites this paper
• Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma.

  2016cites this paper
• Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation.

  2016cites this paper
• Quercetin attenuates the activation of hepatic stellate cells and liver fibrosis in mice through modulation of HMGB1-TLR2/4-NF-κB signaling pathways.

  2016cites this paper
• Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.

  2016cites this paper
• Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice.

  2016cites this paper
• Changes in gut toll-like receptor-4 and nod-like receptor family pyrin domain containing-3 innate pathways in liver cirrhosis rats with bacterial translocation.

  2016cites this paper
• Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis

  2016cites this paper
• Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity.

  2016cites this paper
• Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats

  2016cites this paper
• Intestinal permeability in a patient with liver cirrhosis

  2016cites this paper
• Effects of chlorpyrifos on the gut microbiome and urine metabolome in mouse (Mus musculus).

  2016cites this paper
• Hepatic inflammation and fibrosis: Functional links and key pathways

  2015cites this paper
• Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

  2015cites this paper
• Advances in hepatic stem/progenitor cell biology

  2015cites this paper
• Recent advancement of molecular mechanisms of liver fibrosis

  2015cites this paper
• Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis.

  2015cites this paper
• Lactobacillus fermentum ZYL0401 Attenuates Lipopolysaccharide-Induced Hepatic TNF-α Expression and Liver Injury via an IL-10- and PGE2-EP4-Dependent Mechanism

  2015cites this paper
• The intestinal microbiota and microenvironment in liver.

  2015cites this paper
• Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice

  2015cites this paper
• Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.

  2015cites this paper
• The Gut Microbiota and Liver Disease

  2015cites this paper
• Methods to determine intestinal permeability and bacterial translocation during liver disease.

  2015influential citation
• Role of Gut Microbiota in Liver Disease.

  2015cites this paper
• Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice

  2015cites this paper
• Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer

  2014cites this paper
• Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

  2014cites this paper
• Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

  2014cites this paper